Bio
Pat Arensdorf oversees the establishment of a biorepository with fully integrated clinical and data operations to accelerate development of molecular assays for early lung cancer detection. Pat has thirty years of experience in the diagnostics space. Most recently, he was co-founder and Chief Executive Officer of Exai Bio, a next-generation liquid biopsy company using cell-free RNA to enable the earlier and more accurate diagnosis of cancer.
Previous to Exai Bio, he has been involved in the founding, strategy and executive management of several companies, including Gauss Surgical (acquired by Stryker), ClearNote Health, Critical Diagnostics, Diadexus (acquired by Diazyme), Immumetrix (acquired by CareDx), Tethys Bioscience (acquired by HDL), Intersect ENT (IPO; acquired by Medtronic), and First Medical (acquired by Sigma-Aldrich). He continues to mentor new entrepreneurs in the life sciences and healthtech space at Entrepreneur’s First, a global incubator, and at Stanford, including through Stanford Biodesign.
In addition to his corporate activities, Pat has been actively involved in non-profit research and global health, helping establish the original Chan Zuckerberg Biohub (CZB) in San Francisco, as well as worked as an advisor and consultant to multiple NGOs through Halteres Associates, including the Gates Foundation, FIND, and UNITAID. During the pandemic, he spearheaded a regional home testing initiative for the San Francisco Bay Area in collaboration with the Chan Zuckerberg Initiative, Gates Ventures, and Stanford Medicine.
Pat began his career in finance and strategic consulting in private equity. He received his bachelor's degree in Molecular Biology from Princeton and his masters from the Stanford Graduate School of Business. Born and raised in Hawaii, Pat enjoys returning frequently, and is an avid supporter of national disabled sports (US Power Soccer) and assistance dog organizations (Canine Companions).